axiom.png
Axiom Real-Time Metrics Attending J.P. Morgan Healthcare and Biotech Showcase Conferences
January 08, 2023 22:06 ET | Axiom Real-Time Metrics Inc
TORONTO, Jan. 08, 2023 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics ("Axiom"), a premier provider of unified eClinical solutions and services focused on small-to-medium life science organizations,...
abvc-logo-nasdaq-440x386 (1).png
FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer
January 05, 2023 08:30 ET | ABVC BioPharma, Inc.
FREMONT, CA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
purple-logo2020.png
Purple Biotech and Mor Research Applications Announce Research Collaboration to Identify Promising Investigational Oncology Treatments
January 03, 2023 07:00 ET | Purple Biotech Ltd.
REHOVOT, Israel, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Purple  Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and...
Clinical ink Selecte
Clinical ink Selected for Global Late Phase Parkinson’s Disease Programs
December 15, 2022 08:42 ET | Clinical Ink
Horsham, PA, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Clinical ink, a global life science technology company, has partnered with a leading biopharmaceutical organization focused on Parkinson’s Disease...
InflaRx on large white.jpg
InflaRx Initiates First-in-Human Study with Small Molecule C5aR Inhibitor INF904
November 09, 2022 07:40 ET | InflaRx N.V.
Randomized, double-blind, placebo-controlled Phase I trial of orally administered complement inhibitor INF904 initiatedStudy designed as single ascending dose to determine safety, tolerability and...
scilogo.jpg
SciSparc Announced Positive Interim Results Meeting Primary Endpoints at Phase IIa Study in Alzheimer’s Disease Patients with Agitation
November 07, 2022 08:45 ET | SciSparc Ltd
Meets primary endpoints- SCI-110 administration was found to be safe at all tested dosesSCI-110 treatment was also found to reduce agitation - 75% of patients did not need to use additional medication...
CROSSJECT - CLINICAL
CROSSJECT - CLINICAL DEMONSTRATION OF ZENEO® EFFICIENCY FOR INTRAMUSCULAR INJECTION OF MIDAZOLAM
November 02, 2022 03:00 ET | CROSSJECT
Press release CLINICAL DEMONSTRATION OF ZENEO® EFFICIENCY FOR INTRAMUSCULAR INJECTION OF MIDAZOLAM • Primary endpoints met and results in line with expectations• No impact of clothing on the...
CROSSJECT - Validati
CROSSJECT - Validation clinique de l’efficacité de ZENEO® pour l’injection intramusculaire de midazolam
November 02, 2022 03:00 ET | CROSSJECT
Communiqué de presse Validation clinique de l’efficacité de ZENEO® pour l’injection intramusculaire de midazolam • Paramètres primaires atteints et résultats conformes aux attentes Pas d’impact du...
LOGO.png
IMAC Holdings, Inc. Announces Completion of Third Cohort of its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson’s Disease
September 09, 2022 09:22 ET | IMAC Holdings, Inc.
BRENTWOOD, Tenn., Sept. 09, 2022 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC” or “the Company”), today announces it has completed the third cohort of its Phase 1 clinical trial for...
FCS Physicians to Present at ESMO 2022
Florida Cancer Specialists & Research Institute Physicians Present Cancer Care Advancements at Global Oncology Gathering
September 08, 2022 12:30 ET | Florida Cancer Specialists & Research Institute
Fort Myers, Fla., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Research conducted by Florida Cancer Specialists & Research Institute, LLC (FCS) is among the latest cutting-edge developments and findings...